Last reviewed · How we verify

NCT06097897

Imaging of Vitreous Opacities in Human Eyes

Completed NA Last updated 8 April 2025
What this trial tests

NA trial testing SVO-ID in Floaters in 91 participants. Completed in 18 March 2025.

Timeline
1 April 2024
Primary endpoint
18 March 2025
18 March 2025

Quick facts

Lead sponsorPulseMedica
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment91
Start date1 April 2024
Primary completion18 March 2025
Estimated completion18 March 2025
Sites1 location across Panama

Drugs / interventions tested

Conditions studied

Sponsor

PulseMedica

Who can join

18 and older, any sex, with Floaters or Vitreous Opacities. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Vitreous opacities (VOs), commonly known as floaters, are dark spots that appear in, and may float across your vision. Presently, there is a lack of available data in the literature regarding VOs. This study aims to obtain imaging data of VOs in the population to build an imaging database of VOs to learn more about them.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of SVO-ID

Trials testing the same drug.

Other PulseMedica trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06097897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing